Drug Trial Radar · NCT01731431
Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes
Last checked: Nov 20, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
914
Actual
Start
May 18, 2012
Primary completion
Mar 15, 2017
Study completion Jun 2, 2017
Sponsor
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- URC-CIC Paris Descartes Necker Cochin
- First posted
- Nov 21, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial aims to test whether glibenclamide is non-inferior to insulin for the treatment of gestational diabetes.
Conditions
- Diabetes
- Gestational
Interventions
InsulinOther
GlyburideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite criterion of neonatal complications associated with gestational diabetes: macrosomia or birth weight ≥ 90th percentile for gestational age, neonatal hypoglycemia and neonatal hyperbilirubinemiaTime frame: At birth until neonatal discharge from maternity
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Marie-Victoire Senat
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.